Email this article 
CURRENT APPROACHES TO TREATING HORMONE REFRACTORY PROSTATE CANCER
- Authors: Karyakin O.B.1
-
Affiliations:
- Medical Radiology Research Center, Russian Academy of Medical Sciences, Obninsk
- Issue: Vol 7, No 1 (2011)
- Pages: 101-106
- Section: REVIEW
- Published: 30.03.2011
- URL: https://oncourology.abvpress.ru/oncur/article/view/120
- DOI: https://doi.org/10.17650/1726-9776-2011-7-1-101-106
- ID: 120
Cite item
Full Text
Abstract
Chemotherapy with docetaxel (Taxotere) used alone or in combination with other agents is today the standard of treatment for metastatic hormone refractory prostate cancer (HRPC). Nevertheless, there remain many unsolved problems associated with its use. A search for drugs, their combinations, and new therapy regimens for patients with HRPC is being continued to improve the results of treatment.
About the authors
O. B. Karyakin
Medical Radiology Research Center, Russian Academy of Medical Sciences, Obninsk
Author for correspondence.
Email: karyakin@mrrc.obninsk.ru
Russian Federation
References
Supplementary files
